These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 16619495)

  • 1. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
    Cardillo MR; Di Silverio F; Gentile V
    Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
    Cardillo MR; Monti S; Di Silverio F; Gentile V; Sciarra F; Toscano V
    Anticancer Res; 2003; 23(5A):3825-35. PubMed ID: 14666684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.
    Upadhyay J; Shekarriz B; Nemeth JA; Dong Z; Cummings GD; Fridman R; Sakr W; Grignon DJ; Cher ML
    Clin Cancer Res; 1999 Dec; 5(12):4105-10. PubMed ID: 10632347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
    Määttä M; Soini Y; Liakka A; Autio-Harmainen H
    Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer.
    Pilka R; Norata GD; Domanski H; Andersson C; Hansson S; Eriksson P; Casslén B
    Gynecol Oncol; 2004 Sep; 94(3):661-70. PubMed ID: 15350356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
    Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
    J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia.
    Montironi R; Lucarini G; Castaldini C; Galluzzi CM; Biagini G; Fabris G
    Anticancer Res; 1996; 16(4A):2057-62. PubMed ID: 8712742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
    Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue.
    Jung M; Römer A; Keyszer G; Lein M; Kristiansen G; Schnorr D; Loening SA; Jung K
    Prostate; 2003 May; 55(2):89-98. PubMed ID: 12661033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line.
    Udayakumar TS; Nagle RB; Bowden GT
    Prostate; 2004 Jan; 58(1):66-75. PubMed ID: 14673954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
    Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
    Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
    Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
    Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.
    Daja MM; Niu X; Zhao Z; Brown JM; Russell PJ
    Prostate Cancer Prostatic Dis; 2003; 6(1):15-26. PubMed ID: 12664060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
    Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
    Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
    Cardillo MR; Ippoliti F
    Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
    Forsyth PA; Wong H; Laing TD; Rewcastle NB; Morris DG; Muzik H; Leco KJ; Johnston RN; Brasher PM; Sutherland G; Edwards DR
    Br J Cancer; 1999 Apr; 79(11-12):1828-35. PubMed ID: 10206300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material.
    Haupt LM; Irving RE; Weinstein SR; Irving MG; Griffiths LR
    Mol Cell Probes; 2008 Apr; 22(2):83-9. PubMed ID: 17669621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
    Brehmer B; Biesterfeld S; Jakse G
    Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions.
    Davidson B; Goldberg I; Berner A; Nesland JM; Givant-Horwitz V; Bryne M; Risberg B; Kristensen GB; Tropé CG; Kopolovic J; Reich R
    Am J Clin Pathol; 2001 Apr; 115(4):517-24. PubMed ID: 11293899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.